TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
RBC Capital on Biogen (BIIB): 'We See An EU Approval In 3Q24 As Likely'
June 26, 2024 3:25 PM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $317.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "We believe Leqembi is on track for an EU approval which could add another feather in the franchise's cap and improve... More
RBC Capital Reiterates Outperform Rating on Biogen (BIIB)
June 26, 2024 5:24 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $317.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "As Leqembi's launch remains the NT term focus for BIIB investors, we conducted a survey of 140 Alzheimer's patients and caregivers, eliciting a a unique... More
